Related Experiment Video
Updated: Jul 25, 2025
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Olaparib-Induced Purpuric Drug Eruption in a Patient with Castration-Resistant Prostate Cancer
Mana Sekine1, Hitoshi Terui1, Taku Fujimura1
1Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Abstract:
Olaparib is recently approved as an anti-tumor agent for several cancers, including castration-resistant prostate cancer, which inhibits poly (adenosine diphosphate-ribose) polymerase, a DNA repair factor. Since olaparib is a newly approved drug, there are few reports of skin disorders that may be triggered by olaparib administration. In this report, we present a case with an olaparib-induced drug eruption presenting multiple purpuras on the patient's fingers and fingertips. The present case suggests that olaparib might induce purpura as nonallergic drug eruption.
Insights
Olaparib, a new cancer drug, can cause a rare skin reaction called purpura. This drug eruption, presenting as purple spots on fingers, may not be an allergic reaction.
Area of Science:
- Oncology
- Dermatology
- Pharmacology
Background:
- Olaparib is a novel anti-tumor agent targeting poly (adenosine diphosphate-ribose) polymerase (PARP) in DNA repair.
- Approved for various cancers, including castration-resistant prostate cancer.
- Limited data exists on olaparib-associated dermatological side effects due to its recent approval.
